LTGO Latigo Biotherapeutics, Inc.
Nasdaq · SEC CIK 2056611 · EDGAR
- Bought, last 12 months
- $5.04M 2 purchases by 2 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 7 since 2026-08-10, latest 2026-08-12 16:13
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Foresite Capital Management V, LLC | 10% | $2.52M | — |
| Tananbaum James B. | Dir, 10% | $2.52M | — |
| 5AM Ventures VI, L.P. | 10% | — | — |
| Westlake BioPartners Fund I, L.P. | 10% | — | — |
| SEIDENBERG BETH C | Dir, 10% | — | — |
| Sanofi | 10% | — | — |
Transactions 8
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-08-12 16:13 | 2026-08-10 | LTGO | 5AM Ventures VI, L.P. | 10% | C - Cnv Deriv | — | +7.33M | 2.35M | New | — |
| DMI | 2026-08-12 08:18 | 2026-08-10 | LTGO | Sanofi | 10% | C - Cnv Deriv | — | +672.8K | 672.8K | +6,727,780% | — |
| DMI | 2026-08-11 06:00 | 2026-08-10 | LTGO | Westlake BioPartners Fund I, L.P. | 10% | C - Cnv Deriv | — | +12.70M | 2.09M | New | — |
| DMI | 2026-08-10 20:21 | 2026-08-10 | LTGO | Foresite Capital Management V, LLC | 10% | C - Cnv Deriv | $0.00 | +9.04M | 3.41M | New | $0 |
| DI | 2026-08-10 20:21 | 2026-08-10 | LTGO | Foresite Capital Management V, LLC | 10% | P - Purchase | $18.00 | +140.0K | 2.01M | +7% | +$2.52M |
| DMI | 2026-08-10 20:00 | 2026-08-10 | LTGO | Tananbaum James B. | Dir, 10% | C - Cnv Deriv | — | +9.04M | 3.41M | New | — |
| DI | 2026-08-10 20:00 | 2026-08-10 | LTGO | Tananbaum James B. | Dir, 10% | P - Purchase | $18.00 | +140.0K | 2.01M | +7% | +$2.52M |
| DMI | 2026-08-10 20:00 | 2026-08-10 | LTGO | SEIDENBERG BETH C | Dir, 10% | C - Cnv Deriv | — | +12.70M | 2.09M | New | — |
Purchase Sale Sale after option exercise All abbreviations